Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21541940 | 1.00 | MAPT (0.72) | MAPTRAB9ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL2725735 | 1.00 | MAPT (0.72) | MAPTRAB9ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL1392965 | 0.87 | MAPT (0.89) | MAPTRAB9ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL2723171 | 0.83 | MAPT (1.00) | MAPTRAB9ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL4825456 | 0.83 | MAPT (1.00) | MAPTRAB9ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL31072982 | 0.83 | MAPT (0.64) | MAPTRAB9ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL5380119 | 0.83 | MAPT (0.64) | MAPTRAB9ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL29437400 | 0.83 | MAPT (1.00) | MAPTRAB9ACHRNB4CHRNA3CHRNB2 | |
| Hydrochloric Acid SCHEMBL5036857 | 0.82 | MAPT (0.63) | MAPTRAB9ACHRNB4CHRNA3CHRNB2 | |
| SCHEMBL29742107 | 0.81 | MAPT (0.69) | MAPTRAB9ACHRNB4CHRNA3CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630530-B2 | FGFR inhibitor compound and use thereof | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| EP-4186894-B1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-20230192656-A1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4186894-A1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | Henan Medinno Pharmaceutical Technology Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| CN-108283644-B | Transient protection of normal cells during chemotherapy | G1治疗公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630530-B2 | FGFR inhibitor compound and use thereof | FGFR3, FGFR1, FGFR4 | MAPT 2238/4885RAB9A 1402/4885CHRNB4 4323/4885 |
| US-20230192656-A1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | FGFR3, FGFR1, FGFR4 | MAPT 366/4885RAB9A 1673/4885CHRNB4 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.